AU2013310839B2 - Highly diverse combinatorial antibody libraries - Google Patents

Highly diverse combinatorial antibody libraries Download PDF

Info

Publication number
AU2013310839B2
AU2013310839B2 AU2013310839A AU2013310839A AU2013310839B2 AU 2013310839 B2 AU2013310839 B2 AU 2013310839B2 AU 2013310839 A AU2013310839 A AU 2013310839A AU 2013310839 A AU2013310839 A AU 2013310839A AU 2013310839 B2 AU2013310839 B2 AU 2013310839B2
Authority
AU
Australia
Prior art keywords
antibody
library
human
families
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013310839A
Other languages
English (en)
Other versions
AU2013310839A1 (en
Inventor
Ikbel ACHOUR
Christophe Frederic Jerome Blanchetot
Johannes Joseph Wilhelmus De Haard
Jurgen DEL FAVERO
Khalil EL MAZOUARI
Alex KLARENBEEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2013310839A1 publication Critical patent/AU2013310839A1/en
Assigned to ARGEN-X NV reassignment ARGEN-X NV Amend patent request/document other than specification (104) Assignors: arGEN-X BV
Application granted granted Critical
Publication of AU2013310839B2 publication Critical patent/AU2013310839B2/en
Assigned to ARGENX BVBA reassignment ARGENX BVBA Request for Assignment Assignors: ARGEN-X NV
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
AU2013310839A 2012-08-31 2013-09-02 Highly diverse combinatorial antibody libraries Active AU2013310839B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695819P 2012-08-31 2012-08-31
US61/695,819 2012-08-31
PCT/EP2013/068110 WO2014033304A2 (en) 2012-08-31 2013-09-02 Highly diverse combinatorial antibody libraries

Publications (2)

Publication Number Publication Date
AU2013310839A1 AU2013310839A1 (en) 2015-01-29
AU2013310839B2 true AU2013310839B2 (en) 2017-06-01

Family

ID=49117845

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013310839A Active AU2013310839B2 (en) 2012-08-31 2013-09-02 Highly diverse combinatorial antibody libraries

Country Status (9)

Country Link
US (1) US10040870B2 (cg-RX-API-DMAC7.html)
EP (1) EP2890709A2 (cg-RX-API-DMAC7.html)
JP (1) JP6283030B2 (cg-RX-API-DMAC7.html)
CN (1) CN104583236A (cg-RX-API-DMAC7.html)
AU (1) AU2013310839B2 (cg-RX-API-DMAC7.html)
CA (1) CA2879834A1 (cg-RX-API-DMAC7.html)
IL (1) IL236524B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00138A (cg-RX-API-DMAC7.html)
WO (1) WO2014033304A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
HUE072731T2 (hu) 2016-05-20 2025-12-28 Harpoon Therapeutics Inc Egyszeres láncú variábilis fragmentumú CD3-kötõ proteinek
AU2017268460B2 (en) 2016-05-20 2023-12-14 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
CN110139952B (zh) * 2016-12-09 2022-11-25 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
LT3694529T (lt) 2017-10-13 2024-10-10 Harpoon Therapeutics, Inc. Trispecifiniai baltymai ir panaudojimo būdai
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies
US20110300140A1 (en) * 2008-07-02 2011-12-08 Argen-X B.V. Antigen binding polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2762837C (en) * 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300140A1 (en) * 2008-07-02 2011-12-08 Argen-X B.V. Antigen binding polypeptides
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHOFIELD DARREN J ET AL, "Application of phage display to high throughput antibody generation and characterization", GENOME BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, (20071129), vol. 8, no. 11, ISSN 1465-6906, page R254 *

Also Published As

Publication number Publication date
IN2015DN00138A (cg-RX-API-DMAC7.html) 2015-06-12
US20150166680A1 (en) 2015-06-18
IL236524B (en) 2019-01-31
JP6283030B2 (ja) 2018-02-21
CN104583236A (zh) 2015-04-29
JP2015526495A (ja) 2015-09-10
US10040870B2 (en) 2018-08-07
AU2013310839A1 (en) 2015-01-29
CA2879834A1 (en) 2014-03-06
WO2014033304A3 (en) 2014-05-01
EP2890709A2 (en) 2015-07-08
WO2014033304A2 (en) 2014-03-06
IL236524A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AU2013310839B2 (en) Highly diverse combinatorial antibody libraries
Zhai et al. Synthetic antibodies designed on natural sequence landscapes
Glanville et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire
JP4791960B2 (ja) ルックスルー突然変異誘発
US10125198B2 (en) Method for mass humanization of non-human antibodies
Mathonet et al. The application of next generation sequencing to the understanding of antibody repertoires
Hairul Bahara et al. Construction of a semisynthetic human VH single-domain antibody library and selection of domain antibodies against α-crystalline of mycobacterium tuberculosis
Erasmus et al. A single donor is sufficient to produce a highly functional in vitro antibody library
Skamaki et al. In vitro evolution of antibody affinity via insertional scanning mutagenesis of an entire antibody variable region
Spiliotopoulos et al. Sensitive recovery of recombinant antibody clones after their in silico identification within NGS datasets
Kim et al. Deep sequencing of B cell receptor repertoire
Teixeira et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs
Venet et al. Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences
Larsen et al. Next‐generation approaches to advancing eco‐immunogenomic research in critically endangered primates
JP6665274B2 (ja) 標的分子に結合するポリペプチドの決定方法及び決定システム
Hamidon et al. Immune TB antibody phage display library as a tool to study B cell immunity in TB infections
Soon Lim et al. Immune antibody libraries: manipulating the diverse immune repertoire for antibody discovery
Sun et al. Degenerate primer design to clone the human repertoire of immunoglobulin heavy chain variable regions
WO2025098470A1 (en) Natural and artificial intelligent methods for discovering humanlike nanobodies with low immunogenicity
Ford Uncovering the hidden diversity of antibody heavy chains and their implications for autoantibody mediated disease.
유덕균 Prediction of antigen binding reactivity using supervised learning on clonal enrichment pattern through bio-panning
Lai et al. Synthetic Antibody Engineering: Concepts and Applications
Hearty et al. Recombinant Antibodies for Diagnostic Applications: Design Considerations and Structural Correlates
Sasso et al. Research Article One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARGENX BVBA

Free format text: FORMER OWNER(S): ARGEN-X NV